home | services | immunophenotyping
About our flow cytometry service
We use flow cytometry to analyse cell populations in detail. Our current process includes:
8-colour panels (with plans to introduce 12-colour panels)
forward and side scatter properties of cells
Our antibody panels help us:
identify main cell populations in samples
focus on specific populations to determine:
lineage assignment
stage of differentiation
We look for signs of abnormality, including:
aberrant antigen expression
asynchronous antigen expression
light chain restriction in B-cell populations (helps detect clonal B-lymphoid populations)
How we report results:
For bone marrow and tissue samples:
percentage of populations of interest
phenotype description
For peripheral blood lymphoid populations:
typically includes absolute values
Specimens required for flow cytometry
We accept the following specimens:
Blood (10 mL EDTA) and/or bone marrow (1–2 mL EDTA)
Include an unstained or stained smear preparation for evaluation
This can be the same sample provided for morphology
Bone marrow trephines (in sterile saline or RPMI)*
If bone marrow aspirates are unobtainable or inadequate, bone marrow trephines (in sterile saline or RPMI) can be disaggregated for flow cytometric analysis
Fresh tissue biopsy* or fine needle aspirate (FNA) (1 mL sterile saline or RPMI)
Body fluids in sterile tube (e.g. cerebrospinal fluid, pleural fluid, lavage)
Apheresis collection and/or cord blood (in EDTA or ACD)
Important
*For bone marrow trephine or tissue biopsy, always place the first obtained sample in formalin for primary haematopathology reporting. Use flow cytometry only as a secondary investigation.
Sample preparation and storage
To ensure reliable results:
Analyse samples within 48 hours of collection
Store samples at 4°C before despatch
Process fresh tissue biopsies and body fluids as soon as possible after collection
These steps help preserve marker expression for immunophenotyping and maximise cell viability.
Important
Delayed processing may lead to unreliable or uninterpretable results.
Please phone the laboratory in advance when fresh tissue biopsies or body fluid samples are expected.
Flow cytometry reporting
Our immunophenotyping reports include:
Clinical details from the request form
Sample type and cell population analysed
Percentage of cells with the phenotype of interest, relative to the whole population
Overall interpretation and conclusion
Phenotypes useful for monitoring minimal residual disease or evaluating response
Routine antibody panels
Panel | Identification of cell types |
---|---|
Acute leukaemia panel | T-cells: CD1a, CD2, CD3 (surface and cytoplasmic),CD4, CD5, CD7, CD8, CD99 B-cells: CD9, CD19, CD20, CD22, CD79a(cy) Myeloid: CD11b, CD13, CD14, CD15, CD16, CD33, CD64, CD117, myeloperoxidase (MPO) Blasts: CD34, TdT Others: CD10, CD36, CD45, CD56, CD61, CD123, CD303, CD304, HLA-DR |
Lymphocyte panel | T-cells: CD2, CD3, CD4, CD5, CD7, CD8, PD1, CD30 B-cells: CD19, CD20, CD22, CD23, CD79b, CD103, Kappa/Lambda light chains NK-cells: CD2, CD16, CD56, CD57 Others: CD10, CD11c, CD25, CD38, CD43, CD45, CD81 CD123, CD200, PD1 |
Plasma cell panel | Cytoplasmic Kappa/Lambda, CD19, CD20, CD38, CD45, CD56, CD138 |
Stem cell enumeration | CD34, CD45 |
PNH | GPI-linked antigens: CD24, CD66b (neutrophils) CD14 (monocytes) CD59 (red cells) Fluorescent Aerolysin (FLAER),as required |
Hereditary spherocytosis screening | Eosin-5-maleimide |
Immunological platelet enumeration | CD61 / CD41 ICSH reference method |